| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PFI-1 | GDSC1000 | pan-cancer | AAC | -0.097 | 0.003 |
| mRNA | RO-3306 | GDSC1000 | pan-cancer | AAC | -0.099 | 0.003 |
| mRNA | JQ-1 | GDSC1000 | pan-cancer | AAC | -0.092 | 0.004 |
| mRNA | KIN001-102 | GDSC1000 | pan-cancer | AAC | 0.083 | 0.004 |
| mRNA | tacedinaline | CTRPv2 | pan-cancer | AAC | -0.11 | 0.005 |
| mRNA | CIL55A | CTRPv2 | pan-cancer | AAC | -0.14 | 0.006 |
| mRNA | CI-976 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.007 |
| mRNA | MI-2 | CTRPv2 | pan-cancer | AAC | -0.14 | 0.007 |
| mRNA | Merck60 | CTRPv2 | pan-cancer | AAC | -0.083 | 0.007 |
| mRNA | ISOX:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.094 | 0.007 |